FI3858375T3 - Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää - Google Patents

Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää Download PDF

Info

Publication number
FI3858375T3
FI3858375T3 FIEP20216368.9T FI20216368T FI3858375T3 FI 3858375 T3 FI3858375 T3 FI 3858375T3 FI 20216368 T FI20216368 T FI 20216368T FI 3858375 T3 FI3858375 T3 FI 3858375T3
Authority
FI
Finland
Prior art keywords
rvwf
use according
von willebrand
treatment
willebrand factor
Prior art date
Application number
FIEP20216368.9T
Other languages
English (en)
Finnish (fi)
Inventor
Friedrich Scheiflinger
Peter Turecek
Bruce Ewenstein
Wing Yen Wong
Tobias M Suiter
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of FI3858375T3 publication Critical patent/FI3858375T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
FIEP20216368.9T 2011-06-10 2012-06-11 Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää FI3858375T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US201161523790P 2011-08-15 2011-08-15

Publications (1)

Publication Number Publication Date
FI3858375T3 true FI3858375T3 (fi) 2024-04-17

Family

ID=46321496

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20216368.9T FI3858375T3 (fi) 2011-06-10 2012-06-11 Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää

Country Status (24)

Country Link
US (3) US9272021B2 (enExample)
EP (3) EP3412305B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR20190041032A (enExample)
CN (3) CN103732244A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
BR (1) BR112013031795A2 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3858375T3 (enExample)
ES (3) ES2860450T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL2717905T3 (enExample)
PT (3) PT3412305T (enExample)
RU (2) RU2628537C2 (enExample)
SG (2) SG10201604684WA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190041032A (ko) * 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) * 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
EP4343774A3 (en) 2016-04-15 2024-06-05 Takeda Pharmaceutical Company Limited Method and apparatus for providing a pharmacokinetic drug dosing regiment
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
RU2766118C2 (ru) * 2017-07-07 2022-02-08 Такеда Фармасьютикал Компани Лимитед Лечение пациентов с тяжелой формой болезни фон виллебранда, подвергающихся плановому хирургическому вмешательству, путем введения рекомбинантного ффв
EP4424366A3 (en) * 2017-07-07 2024-12-04 Takeda Pharmaceutical Company Limited Treatment of gastrointestinal bleeding in patients with severe von willebrand disease by administration of recombinant vwf
SG11202006902QA (en) 2018-02-06 2020-08-28 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
EP3768697A1 (en) * 2018-03-21 2021-01-27 Baxalta Incorporated Separation of vwf and vwf propeptide by chromatographic methods
MX2021009114A (es) * 2019-02-01 2021-10-13 Takeda Pharmaceuticals Co Métodos de tratamiento profiláctico que usan factor de von willebrand recombinante (rvwf).
JP2022547556A (ja) * 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
CN115335074A (zh) 2020-02-04 2022-11-11 武田药品工业株式会社 通过施用重组vwf来治疗患有重度冯维勒布兰德病的患者的月经过多
TW202237149A (zh) * 2020-11-24 2022-10-01 美商邦德治療公司 用於治療出血性障礙之組成物及方法
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
EP0218692A4 (en) 1985-04-11 1988-03-22 Childrens Medical Center VON WILLEBRAND FACTOR.
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
AU2005322067B8 (en) * 2004-12-27 2012-07-26 Takeda Pharmaceutical Company Limited Polymer-von Willebrand factor-conjugates
DK1974014T3 (en) 2006-01-04 2017-06-19 Baxalta Inc OLIGOPEPTID-FREE CELL CULTURE MEDIA
ES2392569T3 (es) * 2007-06-13 2012-12-11 Csl Behring Gmbh Uso de preparaciones FVIII estabilizadas VWF para administración extravascular en la terapia y el tratamiento profiláctico de trastornos de hemorragias
EP2222329A1 (en) 2007-11-09 2010-09-01 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
MX2010007150A (es) * 2007-12-28 2010-09-03 Baxter Int Formulaciones del factor de von-willebrand recombinante.
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
ES2531464T3 (es) * 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
KR101772674B1 (ko) 2008-10-21 2017-09-01 박스알타 인코퍼레이티드 동결건조된 재조합 ｖｗｆ 제제
WO2011017414A2 (en) * 2009-08-04 2011-02-10 Baxter International Inc. Transgenic mouse lacking endogenous fviii and vwf - a model of hemophilia a
HRP20180136T1 (hr) 2010-07-08 2018-04-06 Baxalta GmbH POSTUPAK PROIZVODNJE REKOMBINANTNOG VISOKOMOLEKULSKOG vWF U KULTURI STANICA
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
KR20190041032A (ko) * 2011-06-10 2019-04-19 박스알타 인코퍼레이티드 재조합 vwf의 투여에 의한 응고 질환의 치료

Also Published As

Publication number Publication date
DK2717905T3 (en) 2018-07-02
AU2020200026A1 (en) 2020-01-30
EP3858375A1 (en) 2021-08-04
CA2838845C (en) 2019-08-06
US20120316116A1 (en) 2012-12-13
AU2016202299B2 (en) 2017-07-20
MX2013014543A (es) 2014-06-11
LT2717905T (lt) 2018-10-10
SI2717905T1 (sl) 2018-09-28
BR112013031795A2 (pt) 2016-12-20
DK3858375T3 (da) 2024-04-15
KR20200091476A (ko) 2020-07-30
EP3858375B1 (en) 2024-03-20
US9272021B2 (en) 2016-03-01
JP6347468B2 (ja) 2018-06-27
JP6527114B2 (ja) 2019-06-05
AU2012267458A1 (en) 2014-01-09
CN103732244A (zh) 2014-04-16
CA2838845A1 (en) 2012-12-13
JP2019048892A (ja) 2019-03-28
RU2019103386A3 (enExample) 2022-01-24
JP2014516088A (ja) 2014-07-07
CN108210889A (zh) 2018-06-29
ES2860450T3 (es) 2021-10-05
NZ618790A (en) 2015-07-31
KR102319868B1 (ko) 2021-11-01
KR20190041032A (ko) 2019-04-19
RU2680402C2 (ru) 2019-02-21
ES2682249T3 (es) 2018-09-19
PL3412305T3 (pl) 2021-05-31
HRP20180962T1 (hr) 2018-10-19
EP3412305B1 (en) 2021-01-06
HK1257436A1 (zh) 2019-10-18
MX2020000083A (es) 2020-08-06
ES2976169T3 (es) 2024-07-24
EP3412305A1 (en) 2018-12-12
RU2014100107A (ru) 2015-07-20
US20250387455A1 (en) 2025-12-25
AU2016202299A1 (en) 2016-05-05
AU2022201518B2 (en) 2025-07-03
EP2717905A1 (en) 2014-04-16
AR086904A1 (es) 2014-01-29
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
AU2022201518A1 (en) 2022-03-24
PT2717905T (pt) 2018-07-02
TR201808823T4 (tr) 2018-07-23
DK3412305T3 (da) 2021-03-01
HUE039317T2 (hu) 2018-12-28
JP2017019788A (ja) 2017-01-26
PL2717905T3 (pl) 2018-10-31
WO2012171031A1 (en) 2012-12-13
MX350582B (es) 2017-09-11
EP2717905B1 (en) 2018-05-23
PT3858375T (pt) 2024-04-18
RU2019103386A (ru) 2020-08-07
RU2628537C2 (ru) 2017-08-18
CN107412743A (zh) 2017-12-01
SG10202002591QA (en) 2020-05-28
RU2017102679A3 (enExample) 2018-12-19
AU2017206235A1 (en) 2017-08-03
US20160184403A1 (en) 2016-06-30
CN107412743B (zh) 2021-07-02
SG10201604684WA (en) 2016-07-28
RU2017102679A (ru) 2018-12-19
KR20140039285A (ko) 2014-04-01
AU2017206235B2 (en) 2019-10-17
PT3412305T (pt) 2021-01-29

Similar Documents

Publication Publication Date Title
FI3858375T3 (fi) Hyytymishäiriön hoito antamalla rekombinanttia von Willebrand -tekijää
AU2018256635A1 (en) Methods for treating anemia
EP3418386A3 (en) Compositions and methods for inhibiting gene expression of hepatitis b virus
CA2863964C (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2014014840A (es) Peptido - mimeticos de la horquilla beta.
BR112012018116A2 (pt) "hormônios do crescimento com eficácia in vivo prolongada"
EP2853543A8 (en) Anti-blys antibody
WO2013120012A3 (en) Cdim binding proteins and uses thereof
BRPI0713749B8 (pt) formulações oftálmica líquida e não líquida de um antagonista do fator de crescimento endotelial vascular, e, seringa pré-carregada adequada para administração intravítrea
WO2012103038A9 (en) Nanoparticle compositions, formulations thereof, and uses therefor
TN2014000345A1 (en) Pharmaceutical preparation containing an antivirally active dihydroquinazoline derivative
JP2012519182A5 (enExample)
IN2014DN08870A (enExample)
AR088294A1 (es) Determinacion de polimorfismos de un nucleotido simple utiles para predecir la respuesta clinica al acetato de glatiramero
WO2011112732A3 (en) Methods of treating vascular inflammatory disorders
WO2012177660A3 (en) Leukotoxin e/d as a new anti-inflammatory agent and microbicide
HK1216007A1 (zh) 人体生长激素和白蛋白的融合、制剂及其用途
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
UA104484C2 (uk) Противірусна сполука множинної дії, її склад та спосіб лікування вірусних захворювань
AR124709A2 (es) FACTOR DE VON WILLEBRAND RECOMBINANTE (rVWF) ÚTIL EN LA ENFERMEDAD DE VON WILLEBRAND O HEMOFILIA A
NZ609804A (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
Liu et al. Biodegradable Polymeric Nanoparticle Employing a Photodynamic/Photothermal/Thermodynamic Combination Strategy for Treatment of Acute Maxillofacial Wound Infections
WO2016195338A3 (ko) 액정 나노 입자, 이의 제조방법 및 친유성 약물이 봉입된 액정 나노입자를 함유하는 약물 전달 시스템
PL404379A1 (pl) Maść